Merus Announces First Patient Dosed in Phase II Trial of Petosemtamab in 2L CRC

Merus announced that the first patient has been dosed in the Company’s Phase II trial evaluating petosemtamab, a Biclonics® targeting EGFR and LGR5, in combination with standard chemotherapy in second line metastatic colorectal cancer.